Abbas Z.,Abbas M. .2020 .The cost of eliminating hepatitis C in Pakistan. , 8(20) : 30036-324.
Afzal M.S.,Shah Z.H.,Ahmed Z.H.,Infect J. .2015 .Recent HCV genotype changing pattern in the Khyber Pakhtunkhwa province of Pakistan; is it pointing out a forthcoming problem? Braz. , 12 : 312-313.
Brunner N.,Bruggmann P. .2021 .Trends of the global hepatitis C disease Burden: Strategies to achieve elimination. J. Prev. Med, 54 : 251-258.
Butt S.,Idrees M.,Akbar H.,Rehman I.,Awan Z.,Afzal S.,Hussain A.,Shahid M.,Manzoor S.,Rafique S. .2010 .The changing epidemiology pattern and frequency distribution of hepatitis C virus in Pakistan. Infect. Genet, 04 : 595-600.
Campos G.R.F.,Ward J.,Chen S.,Bittar C.,Rodrigues J.P.V.,Martinelli A.D.C.,Souza F.F.,Pereira L.R.L.,Rahal P.,Harris M.,Gen M. .2021 .A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir. , 102 : 001582.
Costa V.D.,Pellegrini P.,Rotman V.,Pittella A.M.,Nunes E.P.,Lago B.V.,Lampe E.,Mello F.C.A. .2019 .Resistance mutationsA30K and Y93N associated with treatment failure with sofosbuvir and daclatasvir for hepatitis C virus infection nonresponder patients: Case reports. Viruses, 11 : 1004.
De-Torres-Santos A.P.,Martins-Silva V.C.,MendesCorrea M.C.,Lemos M.F.,de-Mello-Malta F.,Santana R.A.F.,Dastoli R.A.F.,de-Castro V.F.D.,Pinho J.R.R.,Moreira R.C. .2021 .Prevalence and pattern of resistance in NS5A/NS5B in hepatitis C chronic patients genotype 3 examined at a public health laboratory in the state of São Paulo, Brazil. , 14 : 723-730.
Foster G.R.,Afdhal N.,Roberts S.K.,Brau N.,Gane E.J.,Pianko S.,Lawitz E.,Thompson A.,Shifman M.L.,Cooper C.,Towner W.J.,Conway B.,Ruane P.,Bourliere M.,Asselah T.,Berg T.,Zeuzem S.,Rosenberg W.,Agarwal K.,Stedman C.A.,Mo H.,Dvory-Sobol L.,Wang J.,McNally J.,Osinusi A.,Brainard D.M.,McHutchison J.G.,Mazzotta F.,Tran F.,Gordon S.C.,Patel K.,Reau N.,Mangia A.,Sulkowski M.,Investigators M.,Investigators M. .2015 .Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N. Eng. J. Med, 373 : 2608-2617.
Haqqi A.,Munir R.,Khalid M.,Khurram M.,Zaid M.,Ali M.,Shah Z.H.,Ahmed H.,Afzal M.S. .2019 .Prevalence of hepatitis C virus genotypes in Pakistan: Current scenario and review of literature. Viral Immunol, 32 : 402-413.
Hassanin A.,Kamel S.,Waked I.,Fort M.,GHSP-D- M. .2021 .Egypt's ambitious strategy to eliminate hepatitis C virus: A case study. Glob. Hlth. Sci. Pract, 9 : 187-200.
Hayes C.N.,Imamura M.,Chayama K. .2019 .Management of HCV patients in cases of directacting antiviral failure. Expert Rev. Gastroenterol. Hepatol., 13 : 839-848.
Hernandez D.,Zhou N.,Ueland J.,Monikowski A.,McPhee F. .2012 .Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their efects on the antiviral activity of NS5A inhibitors. J. clin. Virol, 12 : 13-18.
Hezode C.,Chevaliez S.,Scoazec G.,Soulier A.,Varaut A.,Bouvier-Alias M.,Ruiz I.,Roudot-Thoraval F.,Mallat A.,Féray C.,Pawlotsky J.M. .2016 .Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology, 63 : 1809-1816.
Hikita H.,Takehara T. .2020 .NS5A-P32 deletion in hepatitis C genotype 1b infection is the most refractory treatment-mediated amino acid change exhibiting resistance to all NS5A inhibitors. Semin. Liver Dis, 40 : 143-153.
Kan T.,Hashimoto S.,Kawabe N.,Murao M.,Nakano T.,Shimazaki H.,Nakaoka K.,Ohki M.,Takagawa Y.,Kurashita T.,Takamura T.,Yoshioka K. .2016 .The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay. J. Gastroenterol., 51 : 63-70.
Khan M.U.,Sadia H.,Irshad A.,Baig A.A.,Ashiq S.,Zahid B.,Sheikh R.,Roshan S.,Ali A.,Shamas S.,Bhinder M.A. .2020 .Detection, quantification and genotype distribution of HCV patients in Lahore, Pakistan by real-time PCR. , 20 : 16-1152.
Kumar A.,Rajput M.K.,Paliwal D.,Yadav A.,Chhabra R.,Singh S. .1850 .Genotyping and diagnostic methods for hepatitis C virus: A need of low-resource countries. Ind. J. med. Res., 147 : 16-455.
Lahser F.,Galloway A.,Hwang P.,Palcza J.,Brunhofer J.,Wah J.L.,Robertson M.,Barr E.,Black T.,Asante-Appiah E.,Haber B. .2018 .Interim analysis of a 3-years follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevircontaining regimens in participants with chronic HCV infection. , 23 : 593-603.
Makuza J.D.,Jeong D.,Soe P.,Bartlett S.,Héctor A.,García V.,Binka M.,Adu P.,Dushimiyimana D.,Dushimiyimana D.,Maliza C.,Nisingizwe M.P.,Rwibasira G.,Tuyishime A.,Janjua N.Z. .2022 .Impact of COVID-19 pandemic on HCV care cascade in Rwanda: Ecological study from July 2019 to June 2021. , 20 : 25-30.
Malta F.M.,Medeiros-Filho J.E.,Azevedo R.S.,Goncalves L.,Da Silva,Carrilho L.C.,Pinho F.J.,R.R. F.J. .2010 .Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis. Mem. Inst. Oswaldo Cruz, 105 : 92-98.
Martınez A.P.,Garcıa G.,Ridruejo E.,Perez M.J.,Neukam K.,Flichman D.,Lello F.A.D. .2019 .Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina. J. med, 91 : 1970-1978.
Miura M.,Maekawa S.,Sato M.,Komatsu N.,Tatsumi A.,Takano S.,Amemiya F.,Nakayama Y.,Inoue T.,Sakamoto M.,Enomoto N. .2014 .Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol. Res., 44 : E360-7.
Mushtaq S.,Hashmi A.H.,Khan A.,Kazmi S.M. A. .2022 .Emergence and persistence of resistance-associated substitutions in HCV GT3 patients failing direct-acting antivirals. Front, 13 : 894460.
Ohno O.,Mizokami M.,Wu R.R.,Saleh M.G.,Ohba K.,Orito E.,Mukaide M.,Williams R.,Lau J.Y. .1997 .New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a. J. clin. Microbiol, 35 : 201-207.
Patino-Galindo J.A.,Salvatierra K.,GonzalezCandelas K.,Lopez-Labrador F.X. .2016 .Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. , 60 : 15-2416.
Pawlotsky J.M. .2016 .Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology, 04 : 70-86.
Piselli P.,Serraino D.,Fusco M.,Girardi E.,Pirozzi A.,Tofolutti F.,Cimaglia C.,Taborelli M. .2021 .Hepatitis C virus infection and risk of liverrelated and non-liver-related deaths: A populationbased cohort study in Naples, southern Italy. BMC Infect. Dis., 21 : 667.
Rahimi P.,Sharafi H.,Bahramali G.,SajadianFard F.,Asadi N.S.,Alavian S.M.,Mobarakeh V.I.,Moravej S.Z. .2020 .Prevalence of naturallyoccurring NS5A and NS5B resistance-associated substitutions in iranian patients with chronic hepatitis C infection. , 11 : 617375.
Smith D.B.,Bukh J.,Kuiken C.,Muerhof A.S.,Rice C.M.,Stapleton J.T.,Simmonds P. .2014 .Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology, 59 : 318-327.
Soria M.E.,Garcia-Crespo C.,Martínez-González B.,Vázquez-Sirvent L.,Lobo-Vega R.,Ávila A.N.,Gallego I.,Chen Q.,García-Cehic D.,Llorens-Revull M.,Briones C.,Gómez J.,Ferrer-Orta C.,Verdaguer N.,Gregori J.,Rodríguez-Frías F.,Buti M.,Esteban J.I.,Domingo E.,Quer J.,Perales C. .2020 .Amino acid substitutions associated with treatment failure for hepatitis C virus infection. J. clin. Microbiol, 58 : 20-20.
Spengler U. .2017 .Direct antiviral agents (DAAs)-A new age in the treatment of hepatitis C virus infection. Pharmacol, 10 : 118-126.
Torge D.,Bernardi S.,Arcangeli M.,Bianchi S. .2022 .Histopathological features of SARS-CoV-2 in extrapulmonary organ infection: A systematic review of literature. Pathogens, 11 : 867.
Wyles D.L.,Luetkemeyer A.F. .2017 .Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens. Top. Antivir. Med, 25 : 103-109.
Younas S.,Sumrin A.,Hussain N.,Bilal M. .2022 .Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients. J. appl. Microbiol., 00 : 1-9.
Yousaf A.,Ghafoor A.,Fatima N.,Danish M. .2021 .Gender-specific frequency distribution of hepatitis C virus genotypes in Punjab province, Pakistan: A clinically significant descriptive crosssectional study. Cureus, 13 : .
Zeuzem F.,Mizokami M.,Pianko S.,Mangia K.H.,Martin R.,Svarovskaia E.,Dvory-Sobol H.,Doehle B.,Hedskog C.,Yun C.,Brainard D.M.,Knox S.,McHutchison J.G.,Miller M.D.,Mo H.,Chuang W.L.,Jacobson I.,Dore G.,Sulkowski M. .2017 .NS5A resistanceassociated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and efect on treatment outcome. J. Hepatol., 01 : 910-918.
Zia- ,Kow C.H.,Hasan S.S. .2021 .. on viral hepatitis services in Pakistan. Lancet Gastroenterol. Hepatol., 1253(21) : 00006-6.